Radiopharmaceutical Therapy in Metastatic CRPC
Radiopharmaceuticals are used in the treatment of metastatic castration-resistant prostate cancer. In the United States, four bone-seeking radiopharmaceuticals have been approved. Three of these are β-emitters approved for palliative purposes (phosphorus-32, strontium-89, samarium-153-ethylenediamine tetramethylene phosphonic acid). One α-emitter (radium-223) has been approved for prolonged survival in patients with metastatic prostate cancer. Radiopharmaceuticals for bones have been used for decades in combination with chemotherapy, hormones, and bisphosphonates. Current combinations and clinical trials focus primarily on radium-223, assuming that overall survival benefit is related to this radionuclide. In this chapter, the radiopharmaceutical treatment methods will be elaborated.
KeywordsProstate cancer Castration-resistant Clinical trial Drug CRPC
- 14.Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25(5):805–13.CrossRefPubMedGoogle Scholar
- 18.Carrasquillo JA, O'Donoghue JA, Pandit-Taskar N, Humm JL, Rathkopf DE, Slovin SF, et al. Phase I pharmacokinetic and biodistribution study with escalating doses of (2)(2)(3)Ra-dichloride in men with castration-resistant metastatic prostate cancer. Eur J Nucl Med Mol Imaging. 2013;40(9):1384–93.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014;15(12):1397–406.CrossRefPubMedGoogle Scholar
- 23.Lecouvet FE, Geukens D, Stainier A, Jamar F, Jamart J, d'Othee BJ, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol. 2007;25(22):3281–7.CrossRefPubMedGoogle Scholar
- 26.Parker C, Finkelstein SE, Michalski JM, O'Sullivan JM, Bruland O, Vogelzang NJ, et al. Efficacy and safety of Radium-223 dichloride in symptomatic castration-resistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol. 2016;70(5):875–83.CrossRefPubMedGoogle Scholar